

Implementation, Policy and Community Engagement Research Article

Cite this article: Harrison JD, Palmer NRA, Cabrera A, Fleisher P, Wong E, LeSarre M, Grumbach K, Banta J, Tealer L, Reynolds A, Wassmann A, Rose T, and Nguyen T. Addressing the challenges of conducting community-engaged research during COVID-19: Rapid development and evaluation of a COVID-19 Research Patient and Community Advisory Board (PCAB). *Journal of Clinical and Translational Science* 6: e88, 1–9. doi: [10.1017/cts.2022.413](https://doi.org/10.1017/cts.2022.413)

Received: 24 February 2022

Revised: 19 May 2022

Accepted: 31 May 2022

Keywords:

COVID-19; advisory committees; stakeholder engagement; healthcare disparities; translational science


Address for correspondence:

J. D. Harrison, MPH, PHD, Division of Hospital Medicine, University of California San Francisco, 521 Parnassus Avenue, Box 0131, San Francisco, CA 94143, USA.
Email: james.harrison@ucsf.edu

© The Author(s), 2022. Published by Cambridge University Press on behalf of The Association for Clinical and Translational Science. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike licence (<https://creativecommons.org/licenses/by-nc-sa/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is included and the original work is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use.



Addressing the challenges of conducting community-engaged research during COVID-19: Rapid development and evaluation of a COVID-19 Research Patient and Community Advisory Board (PCAB)

James D. Harrison¹ , Nynikka R. A. Palmer^{2,3}, Abby Cabrera⁴, Paula Fleisher⁵, Erica Wong⁵, Monique LeSarre^{6,7}, Kevin Grumbach^{4,5}, Jim Banta⁷, Lisa Tealer⁷, Andrew Reynolds⁷, Arianna Wassmann⁷, Teri Rose⁷ and Tung Nguyen^{5,8}

¹Division of Hospital Medicine, University of California San Francisco, San Francisco, CA, USA; ²Division of General Internal Medicine at San Francisco General Hospital, Department of Medicine, University of California San Francisco, School of Medicine, San Francisco, USA; ³Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA; ⁴Department of Family and Community Medicine, University of California San Francisco, San Francisco, CA, USA; ⁵Clinical and Translational Science Institute, University of California San Francisco, San Francisco, CA, USA; ⁶Rafiki Coalition for Health & Wellness, San Francisco, CA, USA; ⁷COVID-19 Research Patient and Community Advisory Board (PCAB), University of California San Francisco, San Francisco, CA, USA and ⁸Division of General Internal Medicine, University of California San Francisco, San Francisco, CA, USA

Abstract

Introduction: We created a COVID-19 Research Patient and Community Advisory Board (PCAB) to provide patient and community input into clinical and translational research studies. The purpose of this article is to describe the PCAB creation, implementation, and evaluation. **Methods:** We identified PCAB members who had participated in previous stakeholder engaged activities at our institution and invited their participation. We created a systematic consultation process where researchers could submit plain language research summaries and questions for the PCAB. A facilitated 1-hour virtual consultation was then held where PCAB members provided feedback. We assessed satisfaction of PCAB members and researchers who received consultations using surveys. We also reviewed video recordings of PCAB consultations and reflections from team meetings to identify key lessons learned. **Results:** Twenty-seven PCAB members took part in 23 consultation sessions. Twenty-two completed an evaluation survey (81% response rate). Most members agreed or strongly agreed their opinions were valued (86%), it was a productive use of time (86%) and were satisfied (86%). Nineteen researchers completed an evaluation survey (83% response rate). Researchers reported positive experiences of working with the PCAB. Additional insights include limited funding in COVID-19 research for equitable community engagement, deficiencies in researcher communication skills, and a lack of cultural humility incorporated into study activities. **Conclusions:** PCAB members provided recommendations that maximized the patient-centeredness and health equity focus of COVID-19 research. The detailed description of the process of developing, implementing, and evaluating our PCAB can be used as a template for others wishing to replicate this engagement model.

Introduction

Analyses of federal, state, and local data in the USA confirm the burden that the COVID-19 pandemic has placed on Black, Indigenous, and People of Color (BIPOC) [1–4]. This has exacerbated existing health disparities for BIPOC populations who have experienced disproportionately higher rates of infection, hospitalization, and death [5–8].

To address these disparities and the challenges of COVID-19, research, policy, clinical, and patient stakeholder groups are strongly advocating for a more patient-centered and health equity focused research agenda [9]. To achieve this, active engagement and partnerships between patients and communities most impacted by COVID-19 and researchers are required to guide research study development and implementation, as well as the dissemination of research findings.

However, the COVID-19 pandemic has presented unique challenges that have had a significant adverse impact on patient and community engagement in research. These challenges include shelter in-place orders, the rapid transition to virtual platforms for communication, public mistrust of science, as well as the magnification of healthcare disparities. Members of

the British Medical Journal's patient and public advisory panel noted that the "nothing about us without us" principle of patient engagement in research has often been ignored during the COVID-19 pandemic [10]. This was confirmed by a report, published by the National Health Service (NHS) in the United Kingdom, during the early phases of the pandemic that found that the number of studies sponsored by the NHS in which patients were engaged in designing, managing or disseminating research fell from 80% to 22%. This was despite an expectation from the NHS sponsor for involvement of community and patient stakeholders in research [11, 12]. Researchers self-reported that the need to rapidly set up studies prevented or removed the usual need for patient engagement in design, conduct or review [11]. While this perspective may have been justifiable during the very early phases of the pandemic, many current funding calls for COVID-19 research still do not mention the need to include patients or community members as partners [13]. Even as COVID-19 related trials proliferated, many research teams were ill-equipped to recruit BIPOC participants most impacted by COVID-19 [14]. This resulted in researchers mid-study seeking assistance from community engagement programs at academic institutions [15]. This created understandable frustrations from community members at being asked to inform studies midstream instead of being involved as partners from the beginning [15].

Outside of COVID-19 research, there has been a necessity to adapt clinical and translational research on other topics to meet restrictions placed by the COVID-19 public health response. Even prior to COVID-19, patient and community engagement in research was not universal with many researchers not considering engagement an essential part of the research process and often lacked the skills to create and sustain academic-community partnerships [16].

To ensure that research conducted throughout the pandemic remains patient-centered, systematic engagement of patient and community partners must be operationalized. This includes developing strategies where patients and community members can meaningfully engage with researchers to provide input on emerging COVID-19 research, as well as to adapt existing research to a COVID-19 landscape. Therefore, the objective of this article is to describe the rapid implementation and evaluation of a COVID-19 Research Patient and Community Advisory Board (PCAB) at the University of California San Francisco (UCSF). The COVID-19 Research PCAB was created to provide dynamic, multi-layered patient, and community input into clinical and translational research studies.

Materials and Methods

Below, we describe the process of creation and governance of the COVID-19 Research PCAB, the implementation of the research study consultation process, and the design of the evaluation of the PCAB.

Setting and Context

UCSF is a large urban academic medical center and university dedicated exclusively to health sciences. The Accelerating Systematic Stakeholder, Patient, and Institution Research Engagement (ASPIRE) [17] project within the UCSF Clinical and Translational Science Institute (CTSI) [18] seeks to create institutional mechanisms to provide patient and community stakeholder input into clinical and translation research projects.

ASPIRE was funded by the Patient Centered Outcomes Research Institute (PCORI) and facilitated several efforts to understand, and then actively address, structural and systemic institutional barriers related to patient and community engagement in research. At the beginning of the COVID-19 pandemic, ASPIRE leaders noted the rapid emergence of COVID-19 focused research, and, using funds from a PCORI supplement, pivoted to create institutional infrastructure and processes that facilitated patient and community consultation on COVID-19 research studies and institutional policies. Creation of an institutional PCAB was necessary, as while individual Patient & Family Advisory Councils (PFACs) and Community Advisory Boards (CABs) existed prior to the pandemic for specific health system or research projects, few if any were centrally coordinated by the CTSI or were designed for access by researchers across the entire institution. The UCSF Institutional Review Board (IRB) approved activities related to the evaluation of the PCAB.

Creation of the COVID-19 Research PCAB

Recruitment of patient and community advisors to the PCAB

We conducted two forms of outreach to identify and invite potential patient and community members to join the PCAB. Primary outreach involved contacting participants who were currently, or had previously, participated in stakeholder engaged activities at UCSF (e.g., community advisory boards, patient, and family advisory councils) and were known to the UCSF team [19]. Secondary outreach involved contacting the leaders of existing patient and community advisory boards at UCSF and the San Francisco Bay Area to publicize the PCAB opportunity [20]. These leaders were then asked to connect the UCSF team with any interested individuals to follow up with them about joining the PCAB. Ensuring diverse representation was a guiding principle from the outset of recruitment, including diversity related to age, gender, race, ethnicity, sexual orientation, occupation, and life experiences. Given the urgent need to create the PCAB during COVID-19, it was preferable if potential members had previous experience working on an advisory board and/or research projects, though this was not mandatory. Completion of an application form to join the PCAB was not required.

Orientation of patient and community advisors to the PCAB

Potential PCAB members were emailed an invitation and overview of PCAB working procedures. Individuals interested in participating were invited to attend a virtual orientation session where they met the UCSF team, were orientated to PCAB operations, and had an opportunity to have their questions answered. Those who were unable to attend were asked to review a Zoom video recording of the session and if necessary, attend a one-on-one follow-up meeting with a member of the UCSF team. Following orientation, potential members were asked to confirm their willingness to participate on the PCAB.

Ongoing engagement with PCAB members

Communication and engagement with the PCAB members included a biweekly request for availability for future consultation sessions. PCAB members were also asked to participate in a quarterly all-PCAB meeting, which provided opportunities for relationship building between PCAB members and the UCSF team and for the dissemination of program information and updates.




Fig. 1. Overview of COVID-19 research PCAB consultation process. COVID-19 = SAR-CoV-2 coronavirus disease 19; PCAB = Patient and community advisory board; UCSF = University of California San Francisco, CTSI = clinical and translational science institute.

Staffing

The PCAB was managed and coordinated by a team of staff, faculty, and a community investigator. A 0.20 FTE project coordinator and 0.05 FTE program manager was responsible for managing the day-to-day operations including tracking consultation requests, coordinating research consultation sessions, and communicating with PCAB members and researchers. In addition, four UCSF faculty researchers and a community investigator were included as part of the PCAB staffing team.

COVID-19 Research PCAB Proposal Consultation Process

Activities related to coordinating and conducting the research proposal consultation process can be categorized into five distinct domains that are summarized below and in Fig. 1.

Research team engagement and submission of consultation request

The COVID-19 Research PCAB was advertised as a resource to UCSF investigators with COVID-19 research funding via CTSI newsletters and announcements [21]. A dedicated CTSI research consultation services webpage was also created [22]. In addition, the UCSF IRB shared information with the UCSF team about active COVID-19 research studies, including principal investigator name, and the UCSF team sent individual emails to those investigators encouraging them to submit their study for

PCAB consultation. Researchers interested in a PCAB consultation were asked to submit an online consultation request to initiate the process.

Request for information from the study team

Once researchers had completed an online consultation request, they were sent an email asking them to submit 1 to 2 pages of a plain language summary describing their study, up to three focused questions for the PCAB's specific input, and information regarding the stage of project (ideation, protocol development, implementation), funding status, details of any previous or current community input into their study, and their availability to participate in a consultation (see Supplemental Material 1). The plain language summary statement was reviewed by members of the UCSF team, who then worked with the researcher to edit the plain language summary to ensure suitability of language and content for the PCAB, and refine the questions proposed to the PCAB.

Creation of PCAB consultation session panel

Plain language summaries were sent by email to all members of the PCAB by the PCAB coordinator. PCAB members were asked to respond and provide information about their interest in the topic, previous experience/knowledge of the topic, and availability for participating in a consultation session. These responses were reviewed by the UCSF team to select 5 to 7 PCAB members for each consultation session. Other considerations in selecting PCAB

members related to ensuring a diverse panel and fair distribution of opportunity to participate. At this same time, a consultation session chair, facilitator, and note-taker were selected from the UCSF team to participate. Selected PCAB and UCSF team members were asked to review the plain language summary and questions submitted by the research team prior to the consultation session.

Convening of 1-hour PCAB consultation session

A 1-hour virtual PCAB consultation was held via Zoom within 7–10 days of the study team requesting a consultation. There was an expectation that a faculty researcher in addition to study coordinators and staff attend. At the beginning of each consultation, one of the UCSF team members facilitated a welcome, introductions, and provided an overview of the flow of the meeting and the roles of the UCSF team. The facilitator guide is provided in Supplemental Material 2.

Researchers on the study team were then asked to provide a brief 5-minute description of their project and accompanying questions. The facilitator then moderated a 35–40-min discussion allowing PCAB members to provide their input and responses to the questions posed. Researchers were asked to only respond to clarifying questions from the PCAB and to not respond directly to each piece of feedback until the end of the facilitated discussion, thereby maximizing the amount of time for hearing from PCAB members. Researchers were then allocated 10 min to provide their responses and reflections. In the last 5 minutes of the consultation, the meeting chair summarized the main discussion points and adjourned the meeting. Consultations were digitally recorded, and a note-taker recorded the main discussion points. Technical support for PCAB members using Zoom was available if needed.

Post consultation session follow-up

Immediately after each consultation, the UCSF team met to debrief and provide reflections. Within 7 days of the consultation, the research team would receive the minutes of their consultation, and a transcript of messages written in Zoom chat. PCAB members would receive an email thanking them for their participation and were sent \$125 honoraria that acknowledged their expertise and time spent preparing for and participating in each consultation.

Evaluation of the COVID-19 Research PCAB

We created an evaluation working group comprised of the UCSF team and volunteers from the PCAB. The working group identified the following four areas of focus for the evaluation: (1) PCAB processes and operations; (2) PCAB member experience and satisfaction; (3) Researcher experience and satisfaction; and (4) Overall lessons and learnings from COVID-19 Research PCAB.

PCAB processes and operations

To describe PCAB process and operations, we captured the following information: number of PCAB members recruited and their sociodemographic characteristics, number of consultations completed, number of PCAB and researcher participants at each consultation, research topic, and design of studies reviewed.

PCAB member experience and satisfaction

We developed a survey for PCAB members to capture their experiences, perspectives, and suggestions for improvement of the consultation process. The content of the survey was informed by questions from previously developed instruments that evaluated patient

engagement in research from the UCSF CTSI and PCORI [23]. An initial draft survey comprised of 50 questions was sent to academic and community members of the ASPIRE Advisory Board for feedback. The final surveys included 24 fixed and open-ended response questions that assessed PCAB member perspectives of community member-research partnerships, preparedness for consultations, satisfaction with consultations, perceptions of being respected and listened to, and PCAB operational processes (e.g., access to staff, diversity of the PCAB) and sociodemographic characteristics (Supplemental Material 3). Surveys were sent to PCAB members to complete anonymously up to 3 months after PCAB members had participated in a review session. Survey distribution was managed using Qualtrics (Provo, UT) and non-responders were sent two reminders [24].

Researcher experience and satisfaction

We used the same process to develop the researcher survey. The only difference was that the content of surveys was informed by questions from the UCSF CTSI consultation services and community engagement evaluations. The resulting 24 fixed and open-ended response questions assessed researchers' overall experience and satisfaction with the consultation process, interactions with PCAB staff, faculty and members, and the impact of the consultation on their research (Supplemental Material 4). Surveys were sent to researchers immediately after their review session using Qualtrics (Provo, UT) and non-responders were sent two reminders [24].

Overall lessons and learnings from the COVID-19 research PCAB

To understand and describe the lessons and learnings from the PCAB, we accessed the video recordings of review sessions, video recordings of all-PCAB meetings, and minutes from the debriefing sessions conducted by UCSF team members after each review session. We used thematic analysis to systematically identify, analyze and report patterns within the data [25]. Two members of the research team independently performed open coding using a data-driven (inductive) approach. To ensure methodological rigor, reviewers met at regular intervals during analysis to develop a code book and to resolve any coding discrepancies using negotiated consensus [26]. Codes were then grouped into higher order themes.

Results

COVID-19 Research PCAB Processes and Operations

We recruited 32 patients and community members to participate in the PCAB. Twenty were recruited by primary outreach (i.e., currently or previously engaged in stakeholder activities at UCSF) and 12 were recruited by secondary outreach (i.e., through leaders of existing patient and community advisory boards at UCSF and the San Francisco Bay Area). Between June 2020 and June 2021, 23 review sessions were completed, each with 5–7 PCAB members participating. Twenty-seven members participated in at least one review session (84% participation rate). The number of members participating in one review session was 1, 2 sessions were 5, 3 sessions were 4, 4 sessions were 4, 5 sessions were 2, 6 sessions were 4, 7 sessions were 1, 8 sessions were 2, 9 sessions were 1, 11 sessions were 1, and 12 sessions were 2. Twenty-two members participated in ≥ 3 review sessions. Reasons for nonparticipation by the five PCAB members who did not take part in any review sessions were due to scheduling conflicts and/or prioritization by these individuals of other COVID-19 related community engagement activities.

Table 1. Sociodemographic characteristics of COVID-19 research PCAB and researcher evaluation survey respondents

	PCAB members (n = 22)	Researchers (n = 19)
	n (%)	
Mean age (range)	52.9 (29–75)	47.8 (29–83)
Race/ethnicity		
African American/Black	2 (9)	1 (5)
Asian/Asian American	4 (18)	5 (26)
Latino/Hispanic	6 (27)	1 (5)
White	10 (45)	11 (58)
Other	0	2 (11)
Gender		
Female	10 (45)	7 (37)
Male	11 (50)	12 (63)
TransMale/Transman	1 (5)	0
Education		
High School Graduate/GED	1 (5)	–
Some College	1 (5)	–
College Graduate	4 (18)	–
Postgraduate	16 (73)	–
Disability/impairment	4 (18)	2 (11)
Experience on/with PCABs		
None	2 (9)	4 (21)
<1 year	6 (27)	2 (11)
1–2 years	1 (5)	0
2–3 years	1 (5)	1 (5)
3–4 years	1 (5)	2 (11)
4–5 years	3 (14)	3 (16)
>5 years	8 (36)	7 (37)

COVID-19 = SAR-CoV-2 coronavirus disease 19; PCAB = patient and community advisory board; GED = General education development.

Research studies reviewed by the PCAB were broad including vaccine trials, observational studies, and disparities research. Three review sessions focused on informing COVID-19 related institutional research policies and practices. Details of the studies and policies reviewed by the PCAB can be found in Supplemental Material 5.

PCAB Member Experience and Satisfaction

Twenty-two of the 27 PCAB members who participated in at least one session completed an evaluation survey (81% response rate). Sociodemographic characteristics of PCAB members who responded to the survey are shown in Table 1. No PCAB members reported the need to access Zoom-related technical support to access any review sessions. The preponderance of PCAB members agreed or strongly agreed it was a productive and valuable use of their time (86%), they were satisfied with their role in the PCAB (86%), their expectations were met (77%), and they felt they were listened to and valued (82%) (Table 2). When

Table 2. PCAB member evaluation of participation and experiences (n = 22)*

	Strongly disagree/ disagree	Neutral	Strongly agree/ agree
	n (%)		
I am satisfied in my role as a COVID Research PCAB member.	1 (5)	2 (9)	19 (86)
COVID Research PCAB meetings are productive and a valuable use of my time.	0	3 (14)	19 (86)
The meeting times are convenient.	0	2 (9)	20 (91)
My opinions are listened to and valued.	0	4 (18)	18 (82)
The COVID Research PCAB staff are available to me.	0	1 (5)	20 (91)
I am involved with the work of the COVID Research PCAB to the degree that I would like.	4 (18)	2 (9)	16 (73)
My expectations on the COVID Research PCAB is what I expected.	3 (14)	2 (9)	17 (77)
Researchers who present to the COVID Research PCAB actively listen to my experiences and suggestions.	0	4 (18)	16 (73)
The most recent COVID Research PCAB consultation I participated in had diverse representation among the PCAB members.	1 (5)	1 (5)	19 (86)

COVID = SAR-CoV-2 coronavirus disease 19; PCAB = patient and community advisory board. *Where responses are missing from individual questions, percentages do not equal 100%.

asked to provide additional information about their experiences, PCAB members shared a range of perspectives. Some members noted the value of “*shared learnings among PCAB members, researchers and the UCSF team*” during consultations, while others felt sessions highlighted the “*apparent disconnect between researchers and those people being impacted by their research.*” Many PCAB members were hopeful that consultations would lead to “*greater exposure to community views of what is important for COVID-19 research.*”

Researcher Experience and Satisfaction Engaging the PCAB

Nineteen of the 23 researchers who received a consultation completed an evaluation survey (83% response rate). Researchers typically requested a PCAB consultation to ensure community input on their proposal and to determine how the research study could better serve community needs. Other reasons for PCAB engagement were to obtain advice on recruitment strategies and study data collection approaches or materials. Researchers noted the importance of the PCAB and reported very positive experiences related to: (1) their overall experience and value of the PCAB consultation; (2) how it met their expectations for feedback; (3) how well the PCAB consultation services met their needs; and (4) the efficiency of the PCAB review process (Table 3). Researchers also provided examples of the impact of PCAB members feedback and how it influenced their study. This included changes to recruitment strategies, dissemination activities, and community engagement efforts. A summary of the impact of PCAB member feedback is shown in Table 4.

Table 3. Researcher evaluation of PCAB participation and experiences (n = 19)*

	Very dissatisfied/dissatisfied	Neutral	Very satisfied/satisfied
	n (%)		
How satisfied were you with the turnaround time to complete the work in preparation for the consultation? (e.g., lay summary)?	0	0	19 (100)
How satisfied were you with the time taken to schedule your consultation?	0	1 (5)	18 (95)
How satisfied were you with your experience with the PCAB consultation?	0	0	10 (100)
	Not at all/slightly	Moderately	Very/extremely
How well did our services meet your needs	0	0	19 (100)
	Strongly disagree/disagree	Neutral	Strong agree/agree
My expectations for feedback from the PCAB were met	0	0	19 (100)
I learned principles from this consultation that I can apply to other research	0	0	19 (100)
	Not at all/a little	somewhat	Quite a bit/to a great extent
To what extent did you obtain the information you needed from this consultation?	0	0	19 (100)
	Not at all valuable/slightly valuable	Moderately valuable	Very valuable/extremely valuable
How valuable was the COVID PCAB in providing useful suggestions that helped advance your project?	0	1 (5)	13 (68)

COVID-19 = SAR-CoV-2 coronavirus disease 19; PCAB = patient and community advisory board.

*Where responses are missing from individual questions, percentages do not equal 100%.

Table 4. The impact of PCAB member feedback on COVID-19 research studies as reported by researchers

Re-orientation of study aims
<ul style="list-style-type: none"> • We have edited our aims to ensure a health equity focus. • We reframed our study to how best to serve the needs of our community partners and cultivate a positive relationship during these stressful times.
Changes to recruitment and retention strategies
<ul style="list-style-type: none"> • We have expanded the number and types of stakeholders we are going to engage. • We have added an additional study site to our project that serves diverse populations. • We incorporated feedback to revise recruitment flyers. • We have increased and diversified our recruitment strategies. • We are working to develop systems to ensure the selection, retention, and representation of patients from all backgrounds.
Changes to study activities, methods and dissemination activities
<ul style="list-style-type: none"> • It informed ways in which we can help share the data with different communities. • We got several ideas about how to better partner with the community to disseminate results. • We have revised our messaging to provide more information on what happens if people get sick from COVID. • We adapted our screening procedures to ensure access for participants who do not have access to technology (therefore addressing the digital divide). • The discussion informed measures that will now be included that capture patient/community stressors.
Influenced community engagement processes
<ul style="list-style-type: none"> • We have reached out to CBOs in each of the 6 counties experienced in working with Latinx and other high-risk populations. We have established (or are in process of establishing) vendor agreements with CBOs in all counties to compensate them to have promotoras or community health workers perform outreach to households in the high-risk neighborhoods to invite them to participate in the study. • We realize that we should have engaged with community organizations much earlier in the study process. The feedback was invaluable, and we are sprinting to put into place partnerships that in retrospect we wish we had established much earlier in the study process. The pace of COVID research has been frantic, but nonetheless we should have focused on this early in the study process. We will take this lesson to heart in future research of this nature.

COVID-19 = SAR-CoV-2 coronavirus disease 19; PCAB = patient and community advisory board; CBOs = community-based organizations.

Table 5. Summary of lessons learned from PCAB process organized by themes and definition

The importance of creating equal partnerships to develop COVID-19 research
<ul style="list-style-type: none"> Community members must be equal partners (e.g., not just research participants) and involved earlier in the proposal and study development process.
Improving cultural humility of the research team
<ul style="list-style-type: none"> Researchers must acknowledge the burden experienced by PCAB members and the communities they represent (e.g., higher rates of COVID-19 disease, death, and inequities) and associated triggers in these discussions that evoke their experiences with cultural, racial, ethnic, and historical trauma. Cultural humility must inform research study designs.
PCAB feedback became repetitious
<ul style="list-style-type: none"> PCAB member feedback became repetitious highlighting fundamental deficiencies in researchers understanding of the contextual factors/impact of COVID-19 on the patients and communities the studies were seeking to recruit from. Examples include a lack of culturally relevant and language concordant study materials related to recruitment, lack of attention to communities most impacted by COVID-19.
Lack of researcher skills in community engagement
<ul style="list-style-type: none"> Researchers often had limited awareness of basic principles of patient-centered outcomes research and community engagement, including communication in plain language, active listening skills.
Patient and community incentives lacking
<ul style="list-style-type: none"> Incentives for research participation were often not considered, not enough or not appropriate.
Inflexible COVID-19 multi-center studies
<ul style="list-style-type: none"> Multicenter studies were often inflexible at meeting local investigator or community needs. This resulted in potential challenges incorporating PCAB member feedback and truly operationalizing patient-centered research.
Standardized recruitment, activities, and retention strategies are not patient-centered
<ul style="list-style-type: none"> Study protocols were highly standardized but were not humanized to consider the patient and community impact of COVID-19 and study participation requirement. Examples include excessive time commitment required to participate in research activities, expectation for study activities to be completed in participant's home, lack of consideration for the impact of research participation on housing, employment, family safety.
Lack of funding for community-engaged COVID-19 research
<ul style="list-style-type: none"> Overall funding for community-engaged COVID-19 research is lacking.

COVID-19 = SAR-CoV-2 coronavirus disease 19; PCAB = patient and community advisory board.

Overall Lessons and Learnings

Lessons and learnings from the COVID-19 Research PCAB are summarized in Table 5. We noted the importance of creating equal partnerships between community members and researchers during the development of COVID-19 research and policies. However, despite this need, there was a significant lack of allocated funding in studies for community engagement. We also recognized skill deficiencies in researchers related to community engagement, such as providing plain language summaries of research and practicing active listening skills. We found that many multi-center COVID-19 research studies were inflexible at meeting the local needs of research participants and that standardized study recruitment, study activity, and retention strategies were often not patient-centered or culturally appropriate. We also found a lack of cultural humility reflected in proposed study activities that often did not consider the implications of the burden and trauma of COVID-19 experienced by BIPOC communities. Examples include proposed high-touch or high-burden study activities in shared household environments or study activities that could cause potential loss of income or privacy. The lack of cultural understanding often resulted in feedback from the PCAB that challenged the feasibility of many proposed study activities.

Discussion

COVID-19 has reinforced the urgent need to develop a more patient-centered and health equity focused research agenda to address the health inequities exacerbated by the pandemic [9]. Active engagement

between researchers and patients and community members most impacted by COVID-19 is one approach to meeting this need. By leveraging existing institutional capacity and community relationships, we were able to rapidly implement a PCAB that has been accessible to researchers during the development and implementation of COVID-19 research studies and policies. Twenty-seven PCAB members participated in 23 research and policy consultations. Evaluation of the PCAB highlighted high levels of satisfaction and perceived value from both PCAB members and researchers.

The success of the PCAB was possible, despite the persistent and evolving challenges of COVID-19, because we were able to build on existing institutional capacity and relationships established as part of the UCSF CTSI Community Engagement and Health Policy (CE&HP) Program [27]. Engagement awards from PCORI and an award from the NIH Community Engagement Alliance Against COVID-19 program allowed us to leverage the existing relationships and infrastructure to rapidly create a PCAB as a resource for multiple COVID research studies. The PCAB was operational within 6 weeks of a PCORI award, allowing timely and efficient engagement of community members and researchers to meet the urgency of the rapidly evolving pandemic. The fact the PCAB was organized at an institutional level, through the CTSI CE&HP Program, further facilitated a more rapid response rather than expecting individual investigators to conduct their own patient and community engagement. The implementation and sustainability of the PCAB add to a growing list of collaborative efforts between CTSI sites and community partners that have responded to the challenges of COVID-19 [15, 28, 29]. This has included dedicated programs that have listened and responded to community concerns, collected data to describe how COVID-19

has impacted local communities, communicated science, addressed misinformation and strategically engaged public health departments and BIPOC populations in COVID-19 research.

We have been particularly encouraged with the breadth of COVID-related research topics and study designs presented to the PCAB. PCAB members were able to directly interact with researchers and impart their knowledge and expertise. The PCAB structure provides a model that can address the barriers to early involvement of patient and community stakeholders in research that has been reported during the COVID-19 pandemic. The PCAB remains just as important now as it did at the start of the pandemic as we seek to develop research agendas that address the ongoing challenges and health inequities caused by COVID-19 and engage patients and communities as collaborators in this work. Importantly, PCAB consultations also extended to sessions where members provided recommendations to enhance the patient-centeredness of institutional COVID-19 research policies. The opportunities for the PCAB to engage with institutional policy makers, as well as individual research teams, is an important strategy to promote the adoption and sustainability of institution-wide patient and community-engaged research policies and practices. PCAB members reported high levels of satisfaction with the review process, future evaluations of the PCAB may consider if, and how, the nature of feedback changed over the course of the pandemic, or if the participation frequency of PCAB members produced differential feedback. Exploring factors such as these will likely improve our understanding of this specific type of patient and community engagement in research.

As we developed the PCAB, we intentionally invited potential members with diverse backgrounds, and we defined diversity as broadly as possible to capture a range of perspectives. Diverse PCAB membership also provided an important lesson about this model of academic-community engagement. During consultations, PCAB members often described the health, social and economic burden experienced by them and their communities, which resulted in triggers that evoked their individual and collective experiences of cultural, racial, ethnic, and historical trauma. Such reactions by PCAB members are not surprising given that COVID-19 has exacerbated healthcare inequities. However, this observation points to areas where the academic community may need to consider employing a trauma-informed approach to research engagement when partnering with BIPOC communities impacted by COVID-19 [30]. We acknowledge that our sampling and recruitment approach of individuals currently or previously involved in stakeholder-engaged activities limited PCAB membership to those with the franchise to participate, however this was necessary due to the urgent need presented by the COVID-19 pandemic to create a PCAB that could inform and guide research.

The PCAB process revealed that researchers struggled preparing lay language summaries of their projects for PCAB members to review in advance of consultations. This required the UCSF team to work with researchers to create intelligible and succinct information. Similarly, within consultation sessions, we purposely had to hold researcher reactions and responses to the end of each review session to maximize the time for input from PCAB members. We found that if we did not, many researchers launched into lengthy justifications or responses to feedback. Based on these experiences, we recommend better training of both trainees, early career researchers, and established researchers on best practices for conversations with patient and community consultants. This could

include setting and evaluating investigator competencies for community-engaged research [31] and having researchers watch a short video module on ground rules and best practices prior to attending the consultation session.

In summary, by leveraging existing institutional capacity and community relationships, we were able to rapidly implement a COVID-19 Research PCAB. The creation of a systematic consultation process allowed researchers to hear directly from patient and community members who provided valuable insights and recommendations to maximize patient-centered and equity-focused approaches to the conduct of science. Our description of the process of developing, implementing, and evaluating our COVID-19 Research PCAB may be helpful for others wishing to adopt and adapt this model of engagement at their institution.

Supplementary Material. To view supplementary material for this article, please visit <https://doi.org/10.1017/cts.2022.413>.

Acknowledgements. We would like to thank all COVID-19 Research PCAB members for their passion, commitment, expertise and time: Jim Banta, TaNefer Camara, Lowell Caulder, Bilal Chaney, Diane Dooley, Juno Duenas, Ammo Eisu, Justin Flores, David Goldstein, Steve Heilig, Artanesha Jackson, Loren Jones, Stutee Khandelwal, Monique LeSarre, Patricia Levenberg, Devon Low, Leticia Márquez-Magaña, Sabra Matovsky, Ting Pun, Ramon Ramirez, Andrew Reynolds, Teri Rose, Zanna de Sant'Anna, Angela Sun, Adam Sussman, Gina Symczak, Lisa Tealer, Patsy Tito, Renee Underwood, Arianna Wassmann, Hiroshi Yamaguchi, and Jorge Zepeda. We are also grateful to the researchers who received consultations and completed evaluations.

This work was supported by the Patient-Centered Outcomes Research Institute (PCORI) Eugene Washington PCORI Engagement Award (10566-UCSF), the UCSF Clinical and Translational Science Institute funded by the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH UL1TR001872), and an award from the National Institutes of Health, Community Engagement Alliance Against COVID-19 program (Grant 21-312-0217571-66106L). James Harrison was supported in part by the Agency for Healthcare Research and Quality (K12HS026383). Nynikka Palmer was supported in part by the National Cancer Institute/NIH (K01CA211965). The content is solely the responsibility of the authors and does not necessarily represent the official views of PCORI or the NIH. The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Disclosures. The authors have no conflicts of interest to report.

References

1. Mackey K, Ayers CK, Kondo KK, *et al.* Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths. *Annals of Internal Medicine* 2020; **174**(3): 362–373.
2. Tai DBG, Shah A, Doubeni CA, Sia IG, Wieland ML. The disproportionate impact of COVID-19 on racial and ethnic minorities in the United States. *Clinical Infectious Disease* 2021; **72**(4): 703–706.
3. Bamba C, Riordan R, Ford J, Matthews F. The COVID-19 pandemic and health inequalities. *Journal of Epidemiology & Community Health* 2020; **74**(11): 964–968.
4. Dorn AV, Cooney RE, Sabin ML. COVID-19 exacerbating inequalities in the US. *Lancet (London, England)* 2020; **395**(10232): 1243–1244.
5. Yan BW, Hwang AL, Ng F, Chu JN, Tsoh JY, Nguyen TT. Death toll of COVID-19 on Asian Americans: disparities revealed. *Journal of General Internal Medicine* 2021; **36**(11): 3545–3549.
6. Yancy CW. COVID-19 and African Americans. *Journal of the American Medical Association* 2020; **323**(19): 1891–1892.
7. Sze S, Pan D, Nevill CR, *et al.* Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. *eClinicalMedicine* 2020; **29**: 100630.

8. **Arrazola J, Masiello M, Joshi S, et al.** COVID-19 mortality among American Indian and Alaska native persons – 14 states, January – June 2020. *MMR Morbidity and Mortality Weekly Report* 2020; **69**(49): 1853–1856.
9. **Quinn B, Kauh T.** For its health equity agenda, the Biden administration needs research that focuses on impacted communities. *Health Affairs* [Internet], July 13, 2021. (<https://www.healthaffairs.org/doi/10.1377/hblog20210712.23373>)
10. **Richards T, Scowcroft H.** Patient and public involvement in covid-19 policy making. *British Medical Journal* 2020; **370**: m2575.
11. **Denegri S, Starling B.** COVID-19 and patient engagement in health research: what have we learned? *Canadian Medical Association Journal* 2021; **193**(27): E1048–E1049.
12. **National Health Service Health Research Authority.** Public involvement in a pandemic: lessons from the UK COVID-19 public involvement matching service [Internet], last updated November 26, 2021. (<https://www.hra.nhs.uk/planning-and-improving-research/best-practice/public-involvement/public-involvement-pandemic-lessons-uk-covid-19-public-involvement-matching-service/>)
13. **Cukier A.** Patient partnership falling to wayside in COVID-19 research rush. *Canadian Medical Association Journal* 2021; **193**(27): E1054–E1055.
14. **Chastain DB, Osaie SP, Henao-Martinez AF, Franco-Paredes C, Chastain JS, Young HN.** Racial disproportionality in covid clinical trials. *New England Journal of Medicine* 2020; **383**(9): e59.
15. **Grumbach K, Cottler LB, Brown J, et al.** It should not require a pandemic to make community engagement in research leadership essential, not optional. *Journal of Clinical and Translational Science* 2021; **5**(1): e95.
16. **Shea CM, Young TL, Powell BJ, et al.** Researcher readiness for participating in community-engaged core competencies. *Translational Behavioral Medicine* 2017; **7**(3): 393–404.
17. **Patient Centered Outcomes Research Institute (PCORI).** Accelerating systematic stakeholder, patient, and institution research engagement (ASPIRE) [Internet], last updated March 18, 2022. (<https://www.pcori.org/research-results/2018/accelerating-systematic-stakeholder-patient-and-institution-research>)
18. **University of California San Francisco (UCSF).** UCSF Clinical & Translational Science Institute [Internet], 2022. (<https://ctsi.ucsf.edu>)
19. **Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K.** Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. *Administration and Policy in Mental Health* 2015; **42**(5): 533–544.
20. **Parker C, Scott S, Geddes A.** Snowball sampling. In: Atkinson P, Delamont S, Cernat A, Sakshaug J, Williams R, eds. *SAGE Research Methods Foundations*. Thousand Oaks, CA: Sage Publications, 2019, p. 824.
21. **University of California San Francisco (UCSF).** UCSF COVID Research Patient and Community Advisory Board in motion & receives PCORI funding [Internet], June 9, 2020. (<https://ctsi.ucsf.edu/news/ucsf-covid-research-patient-and-community-advisory-board-motion-receives-pcori-funding>)
22. **University of California San Francisco (UCSF).** Community-engaged research consultation [Internet], 2022. (<https://consult.ucsf.edu/community-engaged-research>)
23. **Patient Centered Outcomes Research Institute (PCORI).** Ways of engaging - ENgagement ACTivity Tool (WE-ENACT) - patients and stakeholders 3.0 item pool [Internet], August 1, 2016. (<https://www.pcori.org/sites/default/files/PCORI-WE-ENACT-3-0-Patients-Stakeholders-Item-Pool-080916.pdf>)
24. **Van Mol C.** Improving web survey efficiency: the impact of an extra reminder and reminder content on web survey response. *International Journal of Social Research Methodology* 2017; **20**(4): 317–327.
25. **Vaismoradi M, Turunen H, Bondas T.** Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. *Nursing & Health Science* 2013; **15**(3): 398–405.
26. **Bradley EH, Curry LA, Devers KJ.** Qualitative data analysis for health services research: developing taxonomy, themes, and theory. *Health Services Research* 2007; **42**(4): 1758–1772.
27. **National Center for Advancing Translational Science.** Clinical and Translational Science Awards (CTSA) Program [Internet], 2022. (<https://ncats.nih.gov/ctsa>)
28. **Eder MM, Millay TA, Cottler LB.** A compendium of community engagement responses to the COVID-19 pandemic. *Journal of Clinical and Translational Science* 2021; **5**(1): e133.
29. **Michener L, Aguilar-Gaxiola S, Alberti PM, et al.** Engaging with communities – lessons (re)learned from COVID-19. *Preventing Chronic Disease* 2020; **17**: E65.
30. **Jumarali SN, Nnawulezi N, Royson S, Lippy C, Rivera AN, Toopet T.** Participatory research engagement of vulnerable populations: employing survivor-centered, trauma-informed approaches. *Journal of Participatory Research Methods* 2021; **2**(2). DOI [10.35844/001c.24414](https://doi.org/10.35844/001c.24414)
31. **Matthews AK, Castillo A, Anderson E, et al.** Ready or not? Observations from a long-standing community engagement advisory board about investigator competencies for community-engaged research. *Journal of Clinical and Translational Science* 2018; **2**(3): 129–134.